52 completed, 12 recruiting, 11 not yet recruiting, 11 unknown. 44 Phase 2, 31 Phase 3, 10 Phase 4, 9 Phase 1, 7 Not applicable.
Follow Pyrazinamide: new trials by email Literature Review of Pyrazinamide trials Research Report on Pyrazinamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2027-02-01 | 2026-11-02 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial) Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis (TB) | Phase 3 | Recruiting | University College, London | 784 | 2026-10-12 | 2026-10-26 |
| A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis | Phase 3 | Not yet recruiting | Seoul National University Hospital | 294 | 2026-10-01 | 2026-06-30 |
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg - Pulmonary Tuberculosis (TB) | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 80 | 2026-01-03 | 2026-01-23 |
| Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis RESP30TB, HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) - Pulmonary Tuberculoses | Phase 2 | Recruiting | Thirty Respiratory Limited | 24 | 2025-10-13 | 2026-01-12 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi Silymarin 420 mg, N Acetyl Cysteine, Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) - Drug Induced Liver Injury, Tuberculosis (TB) | Phase 1 | Not yet recruiting | Liaquat National Hospital & Medical College | 410 | 2025-07-01 | 2025-07-10 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis Rifampin, Isoniazid, Rifapentine (RPT) - Mild Spinal Tuberculosis | Phase 2 | Not yet recruiting | Shandong University | 300 | 2025-04-05 | 2025-04-08 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis | Phase 2 | Recruiting | TASK Applied Science | 60 | 2025-03-03 | 2025-03-07 |
| Shortened Regimen for Drug-susceptible TB in Children Isoniazid, Rifampin, Pyrazinamide - Tuberculosis, Tuberculosis, Pulmonary | Phase 3 | Recruiting | Johns Hopkins University | 860 | 2025-01-15 | 2026-07-24 |
| Intensified Short Course Regimen for TBM in Adults High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg - Tuberculous Meningitis | Phase 3 | Not yet recruiting | Indian Council of Medical Research | 372 | 2024-03-01 | 2023-12-21 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
Showing 20 of 99. Sign in to see all of them.
Tuberculosis (61) · Tuberculosis, Pulmonary (47) · HIV Infections (15) · Tuberculosis, Multidrug-Resistant (14) · Acquired Immunodeficiency Syndrome (9) · AIDS-Related Opportunistic Infections (6) · AIDS-Related Complex (2) · Chemical and Drug Induced Liver Injury (2) · Extensively Drug-Resistant Tuberculosis (2) · Latent Tuberculosis (2) · Tuberculosis, Meningeal (2) · Bacterial Infections (1) · Body Weight (1) · Body Weight Changes (1) · Cachexia (1)
National Institute of Allergy and Infectious Diseases (NIAID) (16) · Global Alliance for TB Drug Development (9) · Centers for Disease Control and Prevention (5) · Beijing Chest Hospital (4) · Seoul National University Hospital (4) · Johns Hopkins University (3) · Michael Hoelscher (3) · National University Hospital, Singapore (3) · Obafemi Awolowo University Teaching Hospital (3) · TASK Applied Science (3) · Tuberculosis Research Centre, India (3) · University College, London (3) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2) · All India Institute of Medical Sciences (2) · Huashan Hospital (2)
South Africa (39) · Uganda (20) · India (15) · United States (13) · Tanzania (12) · China (11) · Brazil (10) · Philippines (10) · Vietnam (8) · Peru (7) · Thailand (7) · Georgia (6) · Haiti (6) · Kenya (6) · Zimbabwe (6)
Nicholas Paton (4) · Bolanle A Omotoso, MD (3) · Antonio Rivero, MD PhD (2) · Clifton E Barry, Ph.D. (2) · Felipes Diez, MD (2) · Fernando Lozano, MD PhD (2) · Jose Carlos Escribano, MD (2) · Juan Jose Hernandez, MD (2) · Juan Pasquau, MD (2) · Manuel Marquez, MD (2)
PMID 36808186, PMID 33542052, PMID 38768617, PMID 12809582, PMID 15276398, PMID 15840453, PMID 16470119, PMID 16675781, PMID 16988514, PMID 17928422, PMID 18366444, PMID 18795962, PMID 18989231, PMID 19406981, PMID 19542476, PMID 19588358, PMID 19965813, PMID 20002783, PMID 20156055, PMID 20632458, PMID 21283017, PMID 21494548, PMID 21813327, PMID 22083071, PMID 22116143, PMID 22129166, PMID 22530208, PMID 22828481, PMID 23216571, PMID 23305215, PMID 23317958, PMID 23392467, PMID 23433590, PMID 24099345, PMID 24663014, PMID 24903795, PMID 25162818, PMID 25196020, PMID 25261418, PMID 25407158, PMID 25622149, PMID 25795076, PMID 25950206, PMID 25959631, PMID 25987620, PMID 26038418, PMID 26104205, PMID 26202768, PMID 26400476, PMID 26847437
U01AI068636 (2), 2019 (1), U01AI134585 (1), U01AI170426 (1), U01AI192041 (1)